Abstract
Smad ubiquitylation regulatory factor-1 (Smurf1) is a HECT-type ubiquitin ligase. The role of Smurf1 in cell development and migration, viral autophagy and immune responses has been the subject of intensive study in recent years. Smurf1 regulates multiple biological networks, including TGF-β and BMP signaling pathways, the non-canonical pathway and the Toll-like receptor pathway, and is linked to certain diseases and disorders, such as bone formation and embryonic development disorders. Increasing evidence suggests that Smurf1 could be a good candidate for further translational studies and a potential target for novel drug design. In this review, we summarize the physiological functions of Smurf1 and its associated disorders; and discuss the current state of drug discovery in the context of the ubiquitin-proteasomal system, and feasible pharmaceutical strategies toward Smurf1 and its regulators, as well as RNA interference and structure-based chemical drug selection.
Keywords: Ubiquitylation, Ubiquitin ligase, HECT domain, Nedd4 family, Smurf1.
Current Pharmaceutical Design
Title:Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Volume: 19 Issue: 18
Author(s): Yu Cao and Lingqiang Zhang
Affiliation:
Keywords: Ubiquitylation, Ubiquitin ligase, HECT domain, Nedd4 family, Smurf1.
Abstract: Smad ubiquitylation regulatory factor-1 (Smurf1) is a HECT-type ubiquitin ligase. The role of Smurf1 in cell development and migration, viral autophagy and immune responses has been the subject of intensive study in recent years. Smurf1 regulates multiple biological networks, including TGF-β and BMP signaling pathways, the non-canonical pathway and the Toll-like receptor pathway, and is linked to certain diseases and disorders, such as bone formation and embryonic development disorders. Increasing evidence suggests that Smurf1 could be a good candidate for further translational studies and a potential target for novel drug design. In this review, we summarize the physiological functions of Smurf1 and its associated disorders; and discuss the current state of drug discovery in the context of the ubiquitin-proteasomal system, and feasible pharmaceutical strategies toward Smurf1 and its regulators, as well as RNA interference and structure-based chemical drug selection.
Export Options
About this article
Cite this article as:
Cao Yu and Zhang Lingqiang, Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/1381612811319180007
DOI https://dx.doi.org/10.2174/1381612811319180007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design ETS Proteins and MMPs: Partners in Invasion and Metastasis
Medicinal Chemistry Reviews - Online (Discontinued) Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets FHIT and p53 Status and Response to Platinum-Based Treatment in Advanced Non-Small Cell Lung Cancer
Current Cancer Drug Targets New Optical Molecular Imaging Systems
Current Pharmaceutical Biotechnology Dietary Interventions for Atopic Disorders
Current Pharmaceutical Design Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Inhibition of Human 5-Lipoxygenase and Anti-Neoplastic Effects by 2-Amino-1,4-Benzoquinones
Medicinal Chemistry Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome
Anti-Cancer Agents in Medicinal Chemistry Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Endoscopic Microscopy Using Optical Coherence Tomography
Current Medical Imaging Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick
Mini-Reviews in Medicinal Chemistry Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry